Ubiquitin ligase Nedd4 promotes α-synuclein degradation by the endosomal-lysosomal pathway

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 41, 2011, Pages 17004-17009

  Tofaris, George K ^a,b   Kim, Hyoung Tae ^a   Hourez, Raphael ^a   Jung, Jin Woo ^c   Kim, Kwang Pyo ^c   Goldberg, Alfred L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Konkuk University   (South Korea)

Author keywords

Neurodegeneration; Protein misfolding

Indexed keywords

3 METHYLADENINE; ALPHA SYNUCLEIN; BORTEZOMIB; POLYUBIQUITIN; RNA; UBIQUITIN PROTEIN LIGASE NEDD4;

ARTICLE; AUTOPHAGY; BRAIN; BRAIN REGION; CONTROLLED STUDY; EMBRYO; ENDOSOMAL LYSOSOMAL PATHWAY; ENDOSOME; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PURIFICATION; HUMAN; HUMAN CELL; LEWY BODY; LOCUS CERULEUS; LYSOSOME MEMBRANE; NEUROBLASTOMA CELL; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RNA INTERFERENCE; SACCHAROMYCES CEREVISIAE; SUBSTANTIA NIGRA; UBIQUITINATION;

ALPHA-SYNUCLEIN; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BRAIN; CELL LINE; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; ENDOSOMES; HEK293 CELLS; HUMANS; LEWY BODIES; LOCUS COERULEUS; LYSINE; LYSOSOMES; MICE; MOLECULAR SEQUENCE DATA; PARKINSON DISEASE; RATS; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SUBSTANTIA NIGRA; SUBSTRATE SPECIFICITY; UBIQUITIN-PROTEIN LIGASE COMPLEXES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 80054732644     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1109356108     Document Type: Article

References (37)

1. Tofaris GK, Spillantini MG (2007) Physiological and pathological properties of α- synuclein. Cell Mol Life Sci 64:2194-2201.
2. Dauer W, Przedborski S (2003) Parkinson's disease: Mechanisms and models. Neuron 39:889-909. (Pubitemid 37130207)
3. Nemani VM, et al. (2010) Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65: 66-79.
4. Dächsel JC, et al. (2007) The ups and downs of α-synuclein mRNA expression. Mov Disord 22:293-295. (Pubitemid 46374792)
5. Bennett MC, et al. (1999) Degradation of α-synuclein by proteasome. J Biol Chem 274: 33855-33858.
6. Tofaris GK, Layfield R, Spillantini MG (2001) α-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett 509: 22-26. (Pubitemid 33153074)
7. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC (2003) α-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278:25009-25013. (Pubitemid 37548663)
8. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy. Science 305: 1292-1295. (Pubitemid 39129234)
9. Shimura H, et al. (2001) Ubiquitination of a new form of α-synuclein by parkin from human brain: Implications for Parkinson's disease. Science 293:263-269. (Pubitemid 32694735)
10. Tetzlaff JE, et al. (2008) CHIP targets toxic α-synuclein oligomers for degradation. J Biol Chem 283:17962-17968.
11. Rott R, et al. (2008) Monoubiquitylation of α-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J Biol Chem 283:3316-3328.
12. Mulherkar SA, Sharma J, Jana NR (2009) The ubiquitin ligase E6-AP promotes degradation of α-synuclein. J Neurochem 110:1955-1964.
13. Goldberg AL (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426:895-899.
14. Pickart CM, Fushman D (2004) Polyubiquitin chains: Polymeric protein signals. Curr Opin Chem Biol 8:610-616. (Pubitemid 39535722)
15. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG (2003) Ubiquitination of α-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 278:44405-44411. (Pubitemid 37377190)
16. Rotin D, Kumar S (2009) Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell Biol 10:398-409.
17. Lu PJ, Zhou XZ, Shen M, Lu KP (1999) Function of WW domains as phosphoserine- or phosphothreonine-binding modules. Science 283:1325-1328.
18. Uchiki T, et al. (2009) The ubiquitin-interacting motif protein, S5a, is ubiquitinated by all types of ubiquitin ligases by a mechanism different from typical substrate recognition. J Biol Chem 284:12622-12632.
19. Zhao J, et al. (2007) FoxO3 coordinately activates protein degradation by the autophagic/ lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 6: 472-483. (Pubitemid 350163056)
20. Raiborg CR, Stenmark H (2009) The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 458:445-452.
21. Outeiro TF, Lindquist S (2003) Yeast cells provide insight into α-synuclein biology and pathobiology. Science 302:1772-1775. (Pubitemid 37505742)
22. Cooper AA, et al. (2006) α-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313:324-328. (Pubitemid 44480951)
23. Gitler AD, et al. (2009) α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 41: 308-315.
24. Hoshikawa C, Shichiri M, Nakamori S, Takagi H (2003) A nonconserved Ala401 in the yeast Rsp5 ubiquitin ligase is involved in degradation of Gap1 permease and stressinduced abnormal proteins. Proc Natl Acad Sci USA 100:11505-11510. (Pubitemid 37205966)
25. Belgareh-Touzé N, et al. (2008) Versatile role of the yeast ubiquitin ligase Rsp5p in intracellular trafficking. Biochem Soc Trans 36:791-796.
26. Wang G, Yang J, Huibregtse JM (1999) Functional domains of the Rsp5 ubiquitin-protein ligase. Mol Cell Biol 19:342-352. (Pubitemid 29018436)
27. Kumar S, et al. (1997) cDNA cloning, expression analysis, and mapping of the mouse Nedd4 gene. Genomics 40:435-443. (Pubitemid 27136996)
28. Mak SK, McCormack AL, Manning-Bog AB, Cuervo AM, Di Monte DA (2010) Lysosomal degradation of α-synuclein in vivo. J Biol Chem 285:13621-13629.
29. Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ (2003) Yeast genes that enhance the toxicity of a mutant huntingtin fragment or α-synuclein. Science 302:1769-1772. (Pubitemid 37505741)
30. Kuwahara T, et al. (2008) A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in α-synuclein transgenic C. elegans. Hum Mol Genet 17:2997-3009.
31. Srinivasan BJ, et al. (2008) Whole genome survey of coding SNPs reveals a reproducible pathway determinant of Parkinson's disease. Hum Mutat 30:228-238.
32. Nalls MA, et al.; International Parkinson Disease Genomics Consortium (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet 377:641-649.
33. Sidransky E, et al. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361:1651-1661.
34. Anderson JP, et al. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739-29752. (Pubitemid 44536983)
35. Sang Q, et al. (2006) Nedd4-WW domain-binding protein 5 (Ndfip1) is associated with neuronal survival after acute cortical brain injury. J Neurosci 26:7234-7244.
36. Tofaris GK, et al. (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human α-synuclein (1-120): Implications for Lewy body disorders. J Neurosci 26:3942-3950. (Pubitemid 44315414)
37. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB (2007) Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 27:3338-3346. (Pubitemid 46474139)